The Effect of Liraglutide on the GIT

NCT04008290 on ClinicalTrials.gov · last registry update 2019-07-05

A small phase 4 — 15 participants, against a typical 75. Its estimated completion date, 1 April 2021, has passed with no update to the record. Primary outcome, as filed: MMC activity compared between placebo and treatment with liraglutide. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor type: Other
Enrollment: 15
Started: 2020-04-01
Primary completion: 2021-04-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

MMC activity compared between placebo and treatment with liraglutide

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.